KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Medpace Holdings (MEDP) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Medpace Holdings (MEDP) over the last 11 years, with Q3 2025 value amounting to 22.52%.

  • Medpace Holdings' EBITDA Margin rose 1300.0% to 22.52% in Q3 2025 from the same period last year, while for Sep 2025 it was 22.66%, marking a year-over-year increase of 16100.0%. This contributed to the annual value of 22.51% for FY2024, which is 33700.0% up from last year.
  • Medpace Holdings' EBITDA Margin amounted to 22.52% in Q3 2025, which was up 1300.0% from 22.06% recorded in Q2 2025.
  • In the past 5 years, Medpace Holdings' EBITDA Margin ranged from a high of 24.7% in Q4 2024 and a low of 16.67% during Q2 2021
  • In the last 5 years, Medpace Holdings' EBITDA Margin had a median value of 20.69% in 2022 and averaged 20.49%.
  • Per our database at Business Quant, Medpace Holdings' EBITDA Margin tumbled by -34200bps in 2021 and then skyrocketed by 58900bps in 2024.
  • Over the past 5 years, Medpace Holdings' EBITDA Margin (Quarter) stood at 19.13% in 2021, then rose by 8bps to 20.68% in 2022, then dropped by -9bps to 18.81% in 2023, then surged by 31bps to 24.7% in 2024, then fell by -9bps to 22.52% in 2025.
  • Its EBITDA Margin stands at 22.52% for Q3 2025, versus 22.06% for Q2 2025 and 21.52% for Q1 2025.